Zylox-Tonbridge, a Hong Kong-listed medical technology company specialising in neurovascular and peripheral vascular interventional products, has announced a definitive agreement to acquire Germany-based Optimed Medizinische Instrumente GmbH (Optimed) in a multi-step transaction. Under the agreement, Zylox-Tonbridge has the option to acquire 100 percent equity ownership of Optimed from its existing shareholders.

Optimed, a medical technology company focused on minimally invasive vascular and endourology devices, with nearly 30 years of experience in research, development, manufacturing and global distribution. The company has built a sales and service network across more than 70 countries and maintains long-standing relationships with physicians and opinion leaders, particularly in Europe.

The German medtech firm is recognised for its comprehensive portfolio in the peripheral venous stenting market, including specialised devices for iliofemoral veins, iliac bifurcation and the vena cava. Optimed’s dedicated venous stents are supported by strong clinical evidence, including the sinus-Venous and Steveco trials, which demonstrated significant improvements in quality of life and clinical outcomes compared with conservative treatment in patients with chronic deep venous obstruction.

The acquisition is expected to accelerate Zylox-Tonbridge’s global expansion by creating an integrated platform spanning R&D, manufacturing and commercialisation. By combining the two companies’ sales networks and leveraging Optimed’s established European clinical relationships, the company aims to bring innovative products to market more efficiently while expanding its global reach.

Commenting on the acquisition, Dr Zhao said the deal represents a milestone in the company’s global strategy. He added that combining complementary product portfolios and manufacturing platforms will enable the company to deliver high-quality, innovative and affordable vascular solutions to patients and physicians worldwide, while driving the company’s next phase of growth.

Optimed CEO Rüdiger Hausherr said the partnership reflects a shared strategic vision to address evolving healthcare demands. He noted that combining Optimed’s global footprint with Zylox-Tonbridge’s strong R&D and manufacturing capabilities will create a robust platform to accelerate growth and deliver greater value to clinicians and patients globally.

Hans-Henning von Oertzen, Founder and Managing Partner of Westlake Partners, highlighted that the transaction brings together two highly complementary organisations, positioning them to unlock new opportunities and strengthen their leadership in minimally invasive vascular and endourology solutions.

The transaction is also expected to deliver significant operational and manufacturing synergies, supported by an expanded manufacturing base in Germany to ensure high-quality and reliable supply for European and international markets. Following the closing of the deal, it plans to integrate sales, marketing and customer service teams with Optimed to form a unified global commercial organisation. Rüdiger Hausherr will continue as Chief Executive Officer of Optimed, reporting to Dr Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge.